Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 5 studies | 31% ± 10% | |
oligodendrocyte precursor cell | 5 studies | 31% ± 10% | |
GABAergic neuron | 4 studies | 37% ± 11% | |
endothelial cell | 3 studies | 21% ± 4% | |
epithelial cell | 3 studies | 26% ± 15% | |
retinal rod cell | 3 studies | 28% ± 5% | |
glutamatergic neuron | 3 studies | 50% ± 4% | |
interneuron | 3 studies | 43% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 1403.57 | 180 / 180 | 89% | 2.03 | 382 / 430 |
kidney | 100% | 515.07 | 89 / 89 | 86% | 2.01 | 772 / 901 |
intestine | 100% | 482.05 | 964 / 966 | 80% | 2.03 | 422 / 527 |
breast | 100% | 551.27 | 458 / 459 | 76% | 2.70 | 847 / 1118 |
prostate | 100% | 488.22 | 244 / 245 | 76% | 1.50 | 380 / 502 |
esophagus | 100% | 439.08 | 1440 / 1445 | 72% | 2.16 | 131 / 183 |
uterus | 100% | 685.93 | 170 / 170 | 69% | 2.04 | 316 / 459 |
stomach | 98% | 328.36 | 353 / 359 | 70% | 1.75 | 199 / 286 |
adrenal gland | 98% | 421.03 | 252 / 258 | 66% | 1.19 | 151 / 230 |
brain | 99% | 389.73 | 2611 / 2642 | 54% | 1.59 | 378 / 705 |
thymus | 100% | 567.39 | 651 / 653 | 52% | 0.98 | 317 / 605 |
bladder | 100% | 446.38 | 21 / 21 | 50% | 1.25 | 252 / 504 |
lung | 89% | 233.15 | 514 / 578 | 58% | 1.85 | 666 / 1155 |
pancreas | 100% | 406.00 | 327 / 328 | 44% | 0.69 | 78 / 178 |
liver | 76% | 132.96 | 172 / 226 | 36% | 0.67 | 148 / 406 |
spleen | 100% | 306.52 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.58 | 1 / 1 |
muscle | 100% | 671.84 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 378.58 | 1329 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 386.77 | 1195 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 495.92 | 826 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 2.89 | 40 / 45 |
skin | 72% | 1031.40 | 1305 / 1809 | 8% | 0.14 | 37 / 472 |
eye | 0% | 0 | 0 / 0 | 34% | 0.65 | 27 / 80 |
peripheral blood | 18% | 29.22 | 165 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.14 | 3 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0009435 | Biological process | NAD biosynthetic process |
GO_0009165 | Biological process | nucleotide biosynthetic process |
GO_0034612 | Biological process | response to tumor necrosis factor |
GO_0009611 | Biological process | response to wounding |
GO_0030424 | Cellular component | axon |
GO_0043025 | Cellular component | neuronal cell body |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005739 | Cellular component | mitochondrion |
GO_0004515 | Molecular function | nicotinate-nucleotide adenylyltransferase activity |
GO_0000309 | Molecular function | nicotinamide-nucleotide adenylyltransferase activity |
GO_0005524 | Molecular function | ATP binding |
Gene name | NMNAT3 |
Protein name | Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3 (NMN/NaMN adenylyltransferase 3) (Nicotinamide-nucleotide adenylyltransferase 3) (NMN adenylyltransferase 3) (Nicotinate-nucleotide adenylyltransferase 3) (NaMN adenylyltransferase 3) (EC 2.7.7.18) (Pyridine nucleotide adenylyltransferase 3) (PNAT-3) (EC 2.7.7.1) tRNA-uridine aminocarboxypropyltransferase (EC 2.5.1.25) NMNAT3 protein (Nicotinamide nucleotide adenylyltransferase 3, isoform CRA_e) (cDNA FLJ45569 fis, clone BRTHA3010469, highly similar to Nicotinamide mononucleotide adenylyltransferase 3) Nicotinamide-nucleotide adenylyltransferase (EC 2.7.7.1) (EC 2.7.7.18) Nicotinamide nucleotide adenylyltransferase 3 |
Synonyms | hCG_2022373 FKSG76 |
Description | FUNCTION: Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. Can also use GTP and ITP as nucleotide donors. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity, can use NAD(+), NADH, NaAD, nicotinic acid adenine dinucleotide phosphate (NHD), nicotinamide guanine dinucleotide (NGD) as substrates. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+). Protects against axonal degeneration following injury. . |
Accessions | ENST00000296202.12 [Q96T66-1] Q96T66 ENST00000645507.1 ENST00000514703.5 ENST00000339837.9 [Q96T66-2] ENST00000646611.1 ENST00000511444.5 A0A2R8YE08 ENST00000642987.1 ENST00000645290.1 D6R975 A0A2R8YEU0 ENST00000647257.1 Q49AL4 ENST00000506254.5 ENST00000413939.6 [Q96T66-3] D6REC8 A0A2R8YFG2 D6RGG8 ENST00000509291.5 A0A2R8YGL3 ENST00000643695.2 D6RGH7 D6RHV4 ENST00000704800.1 [Q96T66-1] A0A2R8Y594 ENST00000512391.5 |